In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates ...
Finally, let's turn to the New England Journal of Medicine. Speaking of closing the loop, this is the final analysis of overall survival with pembrolizumab in early-stage triple-negative breast cancer ...
Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...